deterioration of renal function renal dysfunction
Conditions
Interventions
The intervention will consist of a three-week treatment period with eprosartan
600mg and/or rosuvastatin
20 mg. During the renal angiography, L-NMMA will be intrarenally administered
after the regul
Sponsors
Academisch Ziekenhuis Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: o Hypertension (Office blood pressure >140 and/or >90 mmHg or ABPM blood pressure: >125 and/or >80 mmHg) o Age: 18-75 jaar o Creatinin clearance of 60-90 mL/min (Cockcroft-Gault formula) o Renal angiography indicated, based on the following criteria: - Refractory hypertension - Accelerating or malignant hypertension - Elevating serum creatinin after an ACE-inhibitor or ARB - Kidney size
Exclusion criteria
Exclusion criteria: o Primary kidney diseases or urological complaints o Diabetes Mellitus o Chronic inflammatory diseases o Recent infections ( 4 units alcohol a day
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Basal renal perfusion, fractional change in renal perfusion after intrarenal L-NMMA infusion, arterial en venous ADMA, SDMA (symmetric dimethylarginine) and L-arginine concentrations and renal elimination of systemic ADMA, SDMA and L-arginine | — |
Secondary
| Measure | Time frame |
|---|---|
| Microalbuminuria, creatinin clearance, blood pressure, plasma LDL (low density lipoproteins), HDL (high density lipoproteins), triglycerides and total cholesterol concentrations | — |
Countries
Netherlands
Outcome results
None listed